, the drug discovery company focused on cancer and fibrosis, announced on Monday that it had successfully completed dosing on its first cohort of patients undergoing its clinical trial of leading cancer drug, RXC004.
The first-in-man clinical trial for RXC004 is a phase ½ study whose primary objective is to evaluate the safety and tolerability of the drug in patients with malignancies.
RXC004 is known as a porcupine inhibitor, a key enzyme in the Wnt signalling pathway which is implicated in the maintenance of cancer stem cells in multiple cancer types.
Adhering to protocol, the first part of the study entailed the first cohort of patients being administered a dose of 0.5mg. Following a review of the data based on the first cohort given by the Safety Review Committee, the recommendation has been made to now escalate the dose.
Shares in Redx Pharma perked up over 8% following this morning's news.
The AIM-listed firm said recruitment of the second cohort of patients, who will be administered the drug at a higher pre-specified dose RXC004, has already begun.
Lisa Anson, Chief Executive Officer of Redx Pharma commented, "We are pleased that the Safety Review Committee has recommended that we can now escalate the dose in the phase 1 /2 study of RXC004 our oral porcupine inhibitor, and consequently we have begun enrolment of our second cohort of patients as per protocol.
We believe that RXC004 has the potential to offer clinical benefit both as a monotherapy and in combination with standard of care treatments for patients with Wnt-driven advanced solid tumours.”
Ms Anson further added, “We look forward to completing patient enrolment for the phase 1 monotherapy dose-escalation study and announcing results during 2020."
For more News & Updates on Redx Pharma:
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.
Next is ‘weathering the retail storm’ as it enjoyed a rise in half-year profits, the store’s boss revealed, The competition watchdog said JD Sports £90m takeover of Footasylum could lead to “higher prices” and “worse choice” for shoppers, but fell short of explaining its reasons in more detail
Travel firm Thomas Cook has been hit with a last-minute demand, from its banks, to find £200m in extra funding in order to secure its future. The troubled operator hoped to seal a rescue deal this week but without this, the firm is likely to collapse.
Salt Lake Potash explain the significance of producing premium grade water soluble sulphate Of potash from its Lake Way Project. Iconic Labs discuss their strategy and recent deals. Chris Bailey on Next, Diageo & Johnson Matthey. John Meyer on Kodal Minerals, Arc Minerals & BlueJay Mining.